Regenerative Medicine Market measure with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (Market Insight Reports) —
The latest report on ‘Regenerative Medicine market’ collated by Market Study Report, LLC, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the ‘Regenerative Medicine market’. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business.

Request a sample Report of Regenerative Medicine Market at: https://www.marketstudyreport.com/request-a-sample/1695290?utm_source=marketwatch&utm_medium=RV

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

Enquiry about Regenerative Medicine market report before Buying at: https://www.marketstudyreport.com/enquiry-before-buying/1695290?utm_source=marketwatch&utm_medium=RV

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Purchase full report of Regenerative Medicine market at: https://www.marketstudyreport.com/securecheckout/paymenta/1695290?utm_source=marketwatch&utm_medium=RV?msfpaycode=sumsf

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Regenerative Medicine Market share

Read more

Digital Fitness Market Potential Risks and Comprehensive Competitive Strategy Analysis in Different Fields, Report 2020 to 2025

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Digital Fitness Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Digital Fitness Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Digital Fitness market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Digital Fitness industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16706715

In Regional Analysis, the Digital Fitness market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Digital Fitness market throughout the forecast length. The Digital Fitness market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Digital Fitness Market: – https://www.industryresearch.co/enquiry/request-covid19/16706715

Digital Fitness market report provides in-depth data about company Profiles, Digital Fitness launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Digital Fitness market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Digital Fitness market covered in report:

● Garmin, Ltd ● Samsung Electronics Co. Ltd ● Casio ● Fitbit, Inc ● Adidas AG ● Huawei ● Fossil ● Xiaomi ● TicWatch ● Apple, Inc

On the basis of types, the Digital Fitness market from 2015 to 2025 is primarily split into:

● Smartwatches ● Fitness Wristbands ● Smart Clothing ● Smart Shoes ● Others

On the basis of applications, the Digital Fitness market from 2015 to 2025 covers:

● Fitness ● Sports

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16706715

Digital Fitness Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Digital Fitness Market report describes present situation, historical background and future forecast. It Comprehensive data showing Digital Fitness sale, consumption, trade statistics, and prices in the recent years are provided. The Digital Fitness report indicates a wealth of information on Digital Fitness vendors. Digital Fitness Market forecast for next five years, including Market volumes and prices is also provided. Raw Material Supply and Downstream Consumer Information is also included.

At last, report on Digital Fitness Market is a comprehensive analysis of the Market providing

Read more

Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read more

Nuclear Medicine Market Research Report by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Press Release

New York, Dec. 01, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Nuclear Medicine Market Research Report by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05993422/?utm_source=GNW

The Global Nuclear Medicine Market is expected to grow from USD 3,812.67 Million in 2019 to USD 5,701.38 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.93%.

Market Segmentation & Coverage:
This research report categorizes the Nuclear Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Nuclear Medicine Market studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products further studied across PET and SPECT. The Therapeutic Products further studied across Alpha Emitters, Beta Emitters, and Brachytherapy.

Based on Application, the Nuclear Medicine Market studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid.

Based on Geography, the Nuclear Medicine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Nuclear Medicine Market including Australian Nuclear Science & Technology Organization (ANSTO), Bracco Imaging S.p.A, Curium Pharma, Eckert & Ziegler, Eczacibasi-Monrol, GE Healthcare, Jubilant Pharma. LLC, Lantheus Medical Imaging, Inc., Mallinckrodt, Nordion (Canada) Inc., NTP Radioisotopes SOC Ltd., and The Institute for Radioelements (IRE – IRE ELiT).

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Nuclear Medicine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces,

Read more

Trigeminal Neuralgia Treatment Medicine Market Analysis, Overview, Growth, Demand and Forecast Research Report to 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (The Expresswire) —
The report “Trigeminal Neuralgia Treatment Medicine Market” in Global to 2026 – Market Scope, Development, and Predictions offers the most up-to-date industry information on the actual market situation, and future outlook for vision frames and mountings in worldwide.

The research includes historic data from 2020 and forecasts until 2026 which makes the report a valuable resource for industry executives, presentation, sales and product managers, consultants, analysts, and other people looking for key industry data in a readily available document with clearly presented tables and Figures.

Request a sample copy of the report – https://www.absolutereports.com/enquiry/request-sample/16562110

Trigeminal Neuralgia Treatment Medicine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Trigeminal Neuralgia Treatment Medicine business, the date to enter into the Trigeminal Neuralgia Treatment Medicine market, Trigeminal Neuralgia Treatment Medicine product introduction, recent developments, etc.

The Following Manufacturers Are Covered in This Report:

● Novartis Pharma AG ● Sihuan Pharma ● Wuhan Humanwell ● Raybow Pharma ● Jinan Jinda Pharmaceutical ● Sinopharm ● Jiangsu Tohope Pharma ● Yabang Medicine ● Taro ● Torrent Pharmas ● Wockhardt Bio AG ● Apotex Inc ● Teva Pharmas ● Zydus Pharms ● Unique Pharm ● Rubicon ● Sun Pharma Inds ● Glenmark Pharms Ltd ● Breckenride Pharm ● Amneal Pharms

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT – REQUEST SAMPLE

Trigeminal Neuralgia Treatment Medicine Market Breakdown Data by Type

● Carbamazepine ● Oxcarbazepine ● Others

Trigeminal Neuralgia Treatment Medicine Market Data by Application

● Hospitals ● Clinic ● Others

Inquire Or Share Your Questions If Any Before The Purchasing This Report – https://www.absolutereports.com/enquiry/pre-order-enquiry/16562110

Geographic Segmentation

The report offers exhaustive assessment of different region-wise and country-wise Breast Localization Needles markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. Key regions covered in the report are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Breast Localization Needles market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.

Detailed TOC of Global Trigeminal Neuralgia Treatment Medicine Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application

1 Trigeminal Neuralgia Treatment Medicine Market Overview

1.1 Product Overview and Scope of Trigeminal Neuralgia Treatment Medicine

1.2 Trigeminal Neuralgia Treatment Medicine Segment by Type

1.2.1 Global Trigeminal Neuralgia

Read more

Sport Medicine Market Exclusive Profitable Comprehensive Report Cover COVID-19 Updates | Smith & Nephew plc, Stryker Corporation

The MarketWatch News Department was not involved in the creation of this content.

Nov 24, 2020 (WiredRelease via Comtex) —
A consciously conceived and designed business intelligence report titled Global Sport Medicine market 2020 by Manufacturers, Type, and Application, Forecast to 2029 by MarketResearch.biz discloses a succinct analysis of the regional spectrum, market size, and revenue forecast about the market. This report sheds light on the vital developments along with other events happening in the global Sport Medicine market which is marking on the enlargement and opening doors for outlook growth in the coming years.

This is the latest report, covering the current COVID-19/Corona Virus pandemic impact on the market which has affected every aspect of life globally. This has brought along several changes in market conditions and the Business areas. The rapidly changing market scenario and initial and future assessment of the impact are covered in the Sport Medicine market report.

For All-Inclusive Information: Download a FREE sample copy of Sport Medicine Market Report Study 2020-2029 at https://marketresearch.biz/report/sport-medicine-market/request-sample

(Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, list of tables and figures, Impact Analysis of COVID-19, TOC, an outlook to key players of the market and comprising key regions.)

Competitive Analysis:

The major companies are exceedingly focused on innovation in Sport Medicine production technology to enhance ledge life and efficiency. The best long-term development path for Sport Medicine market can be caught by guaranteeing financial pliancy to invest in the optimal strategies and current process improvement.

Key manufacturers are included based on the company profile, sales data and product specifications, etc: Smith & Nephew plc, Stryker Corporation, Johnson & Johnson Private Limited, Arthrex Inc., Conmed Corporation, Zimmer Biomet Holdings, Inc., Breg, Inc., Mueller Sports Medicine, Inc., DJO Global, Inc., Wright, Medical Group N.V.

Each manufacturer or Sport Medicine market player’s growth rate, gross profit margin, and revenue figures is provided in a tabular, simple format for few years and an individual section on Sport Medicine market recent development such as collaboration, mergers, acquisition, and any new service or new product launching in the market is offered.

Sport Medicine Market Segmentation Outlook By product, application, and region:

Global sport medicine market segmentation, by product:
Body Reconstruction and Repair Products
Body Support and Recovery Product
Body Monitoring and Evaluation
Accessories

Global sport medicine market segmentation, by application:
Knee Injuries
Hip Injuries
Shoulder Injuries
Ankle & Foot Injuries
Back & Spine Injuries
Elbow & Wrist Injuries
Other Injuries

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Sport Medicine Market: https://marketresearch.biz/report/sport-medicine-market/covid-19-impact

Regional Analysis:On the idea of geography, the Sport Medicine Market report covers statistics for a couple of geographies inclusive of, North America (U.S., Mexico, Canada) South America (Argentina, Brazil) The Middle East & Africa (South Africa, Saudi Arabia) Asia-Pacific (China, Japan, India, Southeast Asia) Europe (U.K., Spain, Italy, Germany, France, Russia)

In addition, The following years considered for this study to forecast the global Sport Medicine market size are

Read more

San Antonio among the worst cities for allergies, report says

A recent report from an air filter brand listed San Antonio as one of the worst cities in the country to live in for allergy sufferers.

In a report last week, Filterbuy ranked the Alamo City as the seventh-worst city for allergies out the top 100 largest metro areas in the U.S. On a 100-point scale in which a higher score will land a city among the worst, San Antonio received a score of 87.21.

Researchers ranked the cities based on three key factors: pollen counts, allergy medicine use, and the number of allergists in the area. In the report, the data also ranked which city had the worst allergy season during the spring and fall.


READ ALSO: Can this graphic help you determine if you have coronavirus, a cold or allergies?

According to the report, San Antonio is the fourth-worst city for allergies during the fall and the 12th-worst for spring.

Overall, the report listed Richmond, Virginia as the worst city in the country for people with allergies. Scranton, Pennsylvania followed in second, Springfield, Massachusetts claimed the third spot and Hartford, Connecticut was No. 4. McAllen in the Rio Grande Valley and New Haven, Connecticut, were No. 5 and No. 6, respectively.

Filterbuy used data from the Asthma and Allergy Foundation of America’s 2020 Allergy Capitals report, which also listed San Antonio as the seventh-worst city for allergies in March. Researchers also used data from the U.S. Centers for Disease Control and Prevention for the report.

For more information on the report, visit filterbuy.com.

Priscilla Aguirre is a general assignment reporter for MySA.com | [email protected] | @CillaAguirre

Source Article

Read more

Antonio Brown’s physical fitness ‘shocked’ the Bucs, per report

Antonio Brown is just a week away from making his 2020 NFL debut, the closest he’s been to an NFL game in over a year. After being away from football for so long, the recently-signed Tampa Bay Buccaneers wide receiver could’ve had a lot of work to do to get back into game day shape. But just the opposite is true.

Fox Sports’ Jay Glazer reported on Sunday that to the surprise and delight of the Bucs, Brown walked into the facility in peak physical condition.

“As far as physically, they were shocked at how good he looked,” Glazer said. “He is in game shape.”

Brown is a five-time All-Pro and known to be a workout nut. Despite his frequent (and quickly rescinded) retirements, it always seemed clear that Brown wanted to return to the NFL. Staying in excellent physical condition would certainly help that happen faster than if he’d spent the last year eating cheese curls and binge watching “Real Housewives” while camping out on the couch.

As far as getting acclimated to his new team and their game plan, don’t worry. Tom Brady apparently invited Brown to stay in his Tampa mansion, so he’ll be around to help whenever Brown needs it.

Brown’s suspension coming to an end

Brown was suspended in January for eight games for violating the NFL’s personal conduct policy following a fight with a moving company driver that led to burglary and battery charges, but that is far from his only off-the-field issue. Brown has also been accused of rape and sexual misconduct by several different women.

His former personal trainer, Britney Taylor, has accused Brown of raping her and has sued him in civil court. That suit is still ongoing, and The Athletic reports that a trial date of Dec. 14-18 has been set, though it’s likely it will be rescheduled to a later date.

Brown’s eight-week suspension ends after this week, so while he will not be playing in Tampa’s Week 8 game against the New York Giants on Monday Night Football, he will make his debut for the Bucs’ Week 9 game agains the New Orleans Saints.

Antonio Brown’s physical condition reportedly “shocked” the Buccaneers when he first showed up to the facility. (Joe Cavaretta/Sun Sentinel/Tribune News Service via Getty Images)

More from Yahoo Sports:

Source Article

Read more

Emmes Employees Co-Author COVID-19 Vaccine Report for the New England Journal of Medicine

ROCKVILLE, Md., Nov. 2, 2020 /PRNewswire/ — Emmes today announced that it provided the data and statistical analysis support for a Phase 1 clinical trial of an investigational COVID-19 vaccine, mRNA-1273, that enrolled adult volunteers.   The results of this clinical trial were published in the New England Journal of Medicine (NEJM) on September 29.

Three Emmes employees were among the co-authors of the recent report, “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.”  The employees are Jim Albert, lead project manager; Dr. Mat Makowski, senior biostatistician; and Kaitlyn Cross, senior biostatistician.

In its role as the statistical and data collection and coordination center, Emmes managed development of the statistical analysis plan and performed all data analysis. 

The recent NEJM publication focused on the immune response to the vaccine and whether the vaccine produced any adverse effects in two groups of older adults (56 to 70 years or ≥ 71 years). An earlier report in NEJM described findings from a Phase 1 trial of the mRNA-1273 candidate vaccine in adults ages 18 to 55 years old.

According to Albert, “It’s an honor to contribute to a study targeted on finding a vaccine for COVID-19 and to participate in writing two articles published in the prestigious New England Journal of Medicine during the same year.”

He added, “The whole world is watching the results of this and other vaccine trials, as we move closer to finding safe, effective ways to address this devastating disease.”

The first part of the Phase 1 trial, which began in March, tested 45 adults, while the subsequent portion enrolled 40 older adults during April and May.  As described in the Preliminary Report published in NEJM in July, this was a dose-escalation, open-label trial to assess the safety of the mRNA-1273 vaccine and its ability to induce an immune response.  Both papers concluded that adverse effects were predominantly mild or moderate in severity.  The side effects, such as fatigue, chills and headache, were found to be dose-dependent and were more common after the second immunization. According to this Sept. 29 report, volunteers receiving the 100 mcg dose produced a stronger antibody response than the 25 mcg dose. This observation supported the use of the 100 mcg dose vaccine in a Phase 3 trial of the candidate.

The trial was conducted at Kaiser Permanente Washington Health Research Institute in Seattle, the Emory University School of Medicine in Atlanta and the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center in Bethesda, Maryland.  The vaccine was co-developed by researchers at the Vaccine Research Center, NIAID and at Moderna, Inc.  Moderna, Inc. manufactured and provided the vaccine candidate.

“COVID-19 is the latest in a long history of infectious disease research that Emmes has supported,” noted Dr. Christine Dingivan, Emmes president and chief executive officer.  “This includes H1N1 influenza, SARS, Ebola and Zika.  Our team has spent many long hours – nights and weekends – collecting and evaluating the statistical data,

Read more

VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, November 16, 2020 at 8:30am Eastern Time to report third quarter ended September 30, 2020 financial results and to provide a corporate update.

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979

 

Source Article

Read more